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Objectives: To evaluate the role of P-glycoprotein (P-gp) and multidrug-resistant-protein 1 (MRP1) on raltegravir
intracellular drug disposition in CD4+ T cells, investigate the effect of HIV-1 infection on P-gp expression and
correlate HIV-1 viraemia with P-gp activity in primary CD4+ T cell subsets.
Methods: The cellular accumulation ratio of [3H]raltegravir was quantified in CD4+ T cell lines overexpressing
either P-gp (CEM-P-gp) or MRP1 (CEM-MRP1) and in primary CD3+CD4+ T cells with high (P-gphigh) and low
P-gp activity (P-gplow); inhibition of efflux transporters was confirmed by the intracellular retention of calcein-
AM. The correlation of P-gp activity with HIV-1 viraemia was assessed in naive and memory T cell subsets
from 21 HIV-1-infected treatment-naive subjects.
Results: [3H]Raltegravir cellular accumulation ratio decreased in CEM-P-gp cells (P,0.0001). XR9051 (a P-gp inhibi-
tor) and HIV-1 PIs reversed this phenomenon. Primary CD4+P-gphigh cells accumulated less raltegravir
(38.4%+9.6%) than P-gplow cells, whereas XR9051 also reversed this effect. In vitro HIV-1 infection of PBMCs
and stimulation of CD4+ T cells increased P-gp mRNA and P-gp activity, respectively, while primary CD4+P-gphigh
T cells sustained a higher HIV-1 replication than P-gplow cells. A significant correlation between HIV-1 viraemia and
P-gp activity was found in different CD4+ T cell subsets, particularly memory CD4+ T cells (r¼0.792, P,0.0001).
Conclusions: Raltegravir is a substrate of P-gp in CD4+ T cells. Primary CD4+P-gphigh T cells eliminate intracellular
raltegravir more readily than P-gplow cells and HIV-1 viraemia correlates with P-gp overall activity. Specific CD4+P-
gphigh T cell subsets could facilitate the persistence of viral replication in vivo and ultimately promote the appear-
ance of drug resistance.
Introduction
Raltegravir, the first HIV-1 integrase inhibitor (INI) approved by the
FDA in 2007, is a key component of HAART in the treatment of
HIV-1 infection.1 Even though raltegravir-containing HAART has
been mostly associated with favourable clinical and virological
outcomes,2 – 8 treatment failure still occurs.9 Raltegravir needs to
cross the plasma membrane to get into the cytoplasm of
HIV-1-infected cells to block viral integration efficiently. Thus, its
drug efficacy represents the interplay between cellular entry
and efflux processes.10 – 12 It is crucial to understand the efflux
mechanisms that occur in T lymphocytes and other cells suscep-
tible to HIV-1 infection as they could be responsible for elimination
of the drug, limiting its intracellular concentration, and favouring
the emergence of resistant viruses and subsequent HIV-1 therapy
failure.13 Moreover, this efflux transporter activity could influence
the suboptimal penetrance of drugs into viral sanctuaries14 and
the complete elimination of HIV-1 reservoirs in the body.
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Initial pharmacological studies of raltegravir showed a com-
plex pharmacokinetic/pharmacodynamic relationship.4 However,
sustained plasma levels of raltegravir (above IC95), particularly at
the end of the dosing interval, are crucial for an optimal clinical
response.15 – 17 In vitro studies have shown that the drug has a
‘post-antibiotic’ effect,18 which could be associated with low
levels of efflux transport in specific immune cell subsets.
Interestingly, raltegravir shows a low cellular penetration (5%
of blood cells) and its cellular disposition is highly variable
between patients (giving up to 15-fold difference)19 and within
same patients after consecutive evaluations.20 Furthermore, the
specific effect of antiviral drugs with known inhibitory activity of
efflux transporters (i.e. ritonavir) in different CD4+ T cell subsets
has never been addressed.
The best-known efflux pumps of the ATP-binding cassette (ABC)
superfamily of transporters are P-glycoprotein (P-gp; ABCB1, also
known as MDR1) and multidrug resistance related-protein 1
(MRP1; ABCC1). Both have been shown to be involved in the efflux
of HIV-1 PIs21 – 23 and whereas NNRTIs do not seem to be sub-
strates for P-gp, MRP1 could influence their drug disposition in T
cells.24 This efflux function can compromise optimal intracellular
drug concentrations25,26 with potential consequences in drug
resistance and/or viral persistence. To date, only few studies have
specifically addressed the question of how HIV-1 INI are extruded
from cells and have been mostly focused on either CD4+ Tcell lines,
blood–tissue barriers or gastrointestinal model systems.13,27–30
Herein, we aimed to evaluate the role of P-gp and MRP1 on ral-
tegravir intracellular drug disposition in CD4+ T cells, to investi-
gate the effect of cell activation and HIV-1 infection on P-gp
expression, and to correlate HIV-1 viral load with P-gp activity in
primary CD4+ T cell subsets.
Materials and methods
Reagents
The reagents used in uptake and inhibition experiments were raltegravir
and [3H]raltegravir (41 Ci/mmol; 0.53 mCi/mL) (Merck, USA) and
[3H]ritonavir (25.2 Ci/mmol; 1 mCi/mL) (Hartmann Analytics, Germany),
MK571 (MRP1 inhibitor) (Sigma-Aldrich, St Louis, MO, USA), reversan
(MRP1 and P-gp inhibitor), XR9051 and Ko143 [inhibitor of BCRP (ABCG2)
at ,1 mM and of MRP1 and P-gp at .1 mM] (Tocris Biosciences, Bristol,
UK) and the fluorescent dyes calcein-AM and rhodamine-123 (Rho123)
(Invitrogen, Paisley, UK). PIs and NNRTIs were obtained through the AIDS
Research and Reference Reagent Program (NIAID, NIH, USA). The remaining
reagents were purchased from Sigma-Aldrich unless indicated in the text.
Cell culture
The model CD4+ T lymphoblastoid cell lines CEM-CCRF (WT), CEME1000
[MRP1 (ABCC1 gene) overexpressing] and CEMVBL100 [P-gp (ABCB1 gene)
overexpressing] were kindly provided by Prof Dr Ross Davey (Bill Walsh
Cancer Research Laboratories, Royal North Shore Hospital, Sydney,
Australia). CEME1000 cells had been previously obtained by stepwise selec-
tion with epirubicin to a final concentration of 1 mg/mL and CEMVBL100 were
selected with vinblastine to a final concentration of 100 ng/mL.31,32 All
CEM cells were routinely cultured in RPMI 1640 culture medium supple-
mented with 10% heat-inactivated FBS, 2 mM L-glutamine and 100 U/mL
penicillin and 100 mg/mL streptomycin (Gibco BRL; Paisley, Scotland),
and maintained at 378C in a humidified atmosphere containing 5% CO2.
Three or four days prior to use in radiotracer and/or fluorescence sub-
strate(s) accumulation experiments, cells were stained with specific anti-
bodies (anti-MRP1 PE-labelled and anti-P-gp PE-labelled; BD Biosciences)
to ensure that they showed the correspondent phenotype (Figure S1a,
available as Supplementary data at JAC Online). Routinely, cells were cul-
tured at 0.5×106 cells/mL concentration the day before using them.
PBMCs were isolated from HIV-1-seronegative donors by Ficoll-
Hypaque density gradient centrifugation of heparin-treated venous
blood. Cells were stimulated for 3 days by adding 3 mg/mL phytohaem-
agglutinin (PHA; Invitrogen, Paisley, Scotland) and 10 IU/mL IL-2 (Roche,
Basel, Switzerland). All primary cells were maintained in RPMI 1640 sup-
plemented with 2 mM L-glutamine, 20% FBS and 100 U/mL penicillin
and 100 mg/mL streptomycin (Gibco BRL).
Primary blood cells from human donors and HIV-1 patients
PBMCs were obtained from healthy human volunteers and HIV-1-infected
subjects by Ficoll-Hypaque density gradient centrifugation. The study
included cryopreserved PBMCs from 21 HIV-1-infected treatment-naive
subjects. Median plasma HIV-1 RNA was 4.5 log10 copies/mL (IQR¼4.1–
5.3), median CD4+ T cell count was 630 cells/mm3 (IQR¼411–780) and
median CD8 T cell count was 1104 cells/mm3 (IQR¼883–1371).
Ethics
The institutional review board on biomedical research from Hospital
Germans Trias i Pujol (HUGTIP) approved this study (ref. CEI PI-15-154).
All patients involved in this study gave their written informed consent to
participate. The data were fully anonymized in adherence to the Helsinki
Declaration.
Sorting of CD31CD41P-gphigh and P-gplow T cells
PBMCs were isolated from HIV-1-seronegative donors as described and
were resuspended in RPMI 1640 (FBS-free medium) at 30×106 cells/mL
and incubated for 20 min at 378C with the P-gp fluorescent substrate
Rho123 (Invitrogen, Madrid, Spain) at a final concentration of 1 mM.
After the incubation, cells were washed twice in RPMI and cultured in com-
plete medium (RPMI 1640 supplemented with 2 mM L-glutamine, 10% FBS
and 100 U/mL penicillin and 100 mg/mL streptomycin) for 2 h to let the
fluorescent dye (Rho123) be effluxed by P-gp. Cells were stained with
anti-CD3-APC and anti-CD4-PerCP antibodies (BD Biosciences) for 20 min
at 48C in PBS with 1% FBS. After washing, cells were resuspended at
60–80×106 cells/mL with PBS plus 1% FBS for cellular sorting. The two
cell populations of interest were sorted by FACS Aria II based on their
staining in CD3-APC, CD4-PerCP, Rho123; very low Rho123 staining corre-
sponded to CD3+CD4+P-gphigh, whereas high Rho123 staining to
CD3+CD4+P-gplow. The proportion of CD3+CD4+P-gphigh and P-gplow
populations varied a lot from donor to donor, but had an average+SD
of 15.7%+6.2% and 81.3%+7.1%, respectively.
In vitro infection of PBMCs with HIV-1
Four different donors’ PBMCs were pooled and cultured in 10 IU/mL IL-2
alone or in combination with 3 mg/mL PHA during 3 days and then infected
(10×106 cells) with HIV-1NL4-3 (CXCR4-tropic strain) at moi of 0.01 and 0.1
during 4 h at 378C. The excess of virus was washed twice with RPMI com-
plete medium and cells were cultured during 48 h in complete medium.
After this period, 5×106 cell pellets were washed twice in cold 1× PBS
and dry frozen at 2808C until RNA extraction was performed.
Quantitative real-time RT–PCR analysis
Total RNA was isolated from in vitro HIV-1-infected PBMCs using RNeasy
Mini Kit (Qiagen, Barcelona, Spain). RNA was treated with DNase I from
RNase-Free DNase Set (Qiagen) to eliminate contaminating DNA.
In total, 1 mg of RNA was retrotranscribed to cDNA using the TaqMan
reverse transcription reagents (including Multiscribe reverse transcriptase
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and random hexamers) as described by the manufacturer (Applied
Biosystems, Foster City, CA, USA). Quantitative real-time PCR was
conducted using pre-made TaqMan probes (Applied Biosystems)
(00184500_m1, P-gp, ABCB1; 14310884E, glyceraldehyde-3-phosphate
dehydrogenase, GAPDH) in a ABI Prism 7700 sequence detection system
(Applied Biosystems) and DDCt method was applied to obtain a relative
quantification of the mRNA levels, according to the TaqMan user’s manual
and as previously described.30 GAPDH was used as the housekeeping gene.
Intracellular accumulation ratio experiments
with radiolabelled raltegravir and ritonavir
The transport and accumulation of [3H]raltegravir (1 mM, 1 mCi/mL) or 1 mM
[3H]ritonavir (1 mM, 1 mCi/mL) was measured by incubating CEM, CEM-MRP1
and CEM-P-gp cells in a final volume of 500 mL of transport medium (137 mM
choline chloride plus 5.4 mM KCl, 1.8 mM CaCl2, 1.2 mM MgSO4 and 10 mM
HEPES, pH 7.4) at 378C (in a water bath) for 30 min in the absence or presence
of fixed concentrations of the following inhibitors: XR9051 (10 mM, P-gp
inhibitor), MK571 (100 mM, MRP1 inhibitor), reversan (10 mM, MRP1 and
P-gp inhibitor) and/or Ko143 (inhibitor of BCRP, MRP1 and P-gp at .1 mM).
We also used the PIs saquinavir and ritonavir, and cold (non-radiolabelled)
raltegravir as cis inhibitors at 100 mM. Similarly, for primary PBMCs, sorted
CD3+CD4+, CD3+CD4+P-gphigh or CD3+CD4+P-gplow cells were incubated
for 30 min at 378C in transport medium containing [3H]raltegravir (1 mM,
1 mCi/mL) and in the absence or presence of XR9051 (1 mM). After incubation,
samples were centrifuged at 12000 rpm for 2 min at 48C. A 200 mL aliquot of
the medium was taken for scintillation counting and the pellets were washed
three times in ice-cold PBS before solubilization for radioactivity counting.
Data were expressed as the cellular accumulation ratio (CAR) as previously
reported.33
Calcein accumulation assays in flow cytometry and
fluorescence microscopy: inhibition with specific
inhibitors and antiviral drugs
To determine the inhibitory potency of a panel of anti-HIV-1 drugs to P-gp/
MRP1 efflux activity (raltegravir, PIs and NNRTIs) we performed calcein-AM
fluorescence accumulation assays. The method is based on the dye cal-
cein as a substrate for ABC efflux pumps MRP1 and P-gp.34
CEM-CCRF cells and its ABC overexpressing variants (0.25×106 CEM
cells/well in V bottom 96-well plates for flow cytometry experiments;
0.75×106 CEM cells/well in 48-well plates for fluorescence microscopy
analysis) were incubated in the absence (control) or presence of inhibitors
(different concentrations depending on the drug/assay) or antiviral drugs
(at 100 mM) and calcein-AM (0.25 mM final concentration) at the same
time. Following 30 min of incubation at 378C, the cells were centrifuged
(1400 rpm, 5 min) and washed twice in ice-cold PBS plus 1% FBS. Finally,
cells were fixed with 100 mL ice-cold 1% paraformaldehyde solution in PBS
and the cell preparations for fluorescence microscopy were mounted on to
poly-L-lysine pretreated glass slides. The calcein fluorescence was moni-
tored by an LSRII flow cytometer (Becton Dickinson). Cells were also eval-
uated in a fluorescence microscope Nikon Eclipse TE200.
Immunophenotype staining of HIV-1-seronegative blood
donors and HIV-1-infected subjects
To characterize the HIV-1 co-receptors surface expression and to establish
correlation of different subsets of CD3+CD4+ T cells with P-gp activity, we
used two different panels of antibodies and Rho123 as P-gp fluorescent
substrate. After isolating the PBMCs from HIV-1-seronegative donors
and HIV-1-infected subjects, cells were resuspended in RPMI 1640 and
stained with Rho123 as described in the previous section. Cells were
then stained with two panels of antibodies: (i) Rho123 (FL1 channel),
anti-CD4-APC, anti-CXCR4-PE, anti-CCR5-PerCP-Cy5.5 and anti-CD3-APC-Cy7
(all from Becton Dickinson); and (ii) anti-CD4-APC, anti-CCR7-PerCP-Cy5.5,
anti-CD45RA-PE-Cy7, anti-CD27-V450/Pacific Blue and anti-CD3-APC-Cy7
(Becton Dickinson). After washing the excess of antibodies, cells were run
on a LSRII flow cytometer (Becton Dickinson) and results analysed by
FlowJo Software (vX.0.7) and GraphPad Prism 6. Statistical analysis for
each staining and graph are detailed in the figure legends.
Results
[3H]Raltegravir time-course and CAR in CEM cells
First, we performed time-course experiments of [3H]raltegravir in
our CD4+ T cell model cell lines (CEM-WT and CEM-P-gp cells) to
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Figure 1. Time-course and inhibition of [3H]raltegravir efflux in CEM cells. (a) [3H]Raltegravir (1 mM; 0.5 mCi/mL) CAR was performed at different time
points (1, 5, 15, 30, 45 and 60 min) in CEM-WT and CEM-P-gp in the absence and presence of 1 mM of the P-gp inhibitor XR9051. (b) CAR (%,
normalized to CEM-WT, control cells) at 30 min was assessed in CEM-WT, CEM-MRP1 and CEM-P-gp in the absence (control) and presence of
MRP1-specific (MK571) and P-gp-specific (XR9051) inhibitors. (c) [3H]Ritonavir (1 mM; 1 mCi/mL) CAR (%, normalized to CEM-WT, control) was
performed in the same cells in the absence (control) or presence of the MRP1/P-gp dual inhibitor reversan. The results represent the mean+SEM of
at least three independent experiments in duplicate. Statistical significance between control in CEM-WT, CEM-MRP1 or CEM-P-gp and between
control and treatment in CEM-MRP1 and P-gp was assessed by paired t-test (*P,0.05; **P,0.01; ***P,0.001; ****P,0.0001). Ctrl, control.
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confirm the role of P-gp in raltegravir efflux. As shown in
Figure 1(a), the CAR of raltegravir (a direct measure of intracellular
accumulation of the drug) was significantly higher in CEM-WTcells
than in CEM-P-gp cells at any time chosen (i.e. 3.12+0.12 versus
1.59+0.96 at 30 min). Most importantly, when co-incubating the
CEM-P-gp cells with XR9051 (1 mM), a highly potent and specific
inhibitor of P-gp activity, the intracellular accumulation of
[3H]raltegravir significantly increased, the effect being more
remarkable at longer incubation times (i.e. 1.59+0.10 versus
2.46+0.10, P¼0.0025 at 30 min). The same treatment with
XR9051 on CEM-WT did not significantly alter [3H]raltegravir CAR
(data not shown). In addition, after re-confirming overexpression
of MRP1 and P-gp by flow cytometry (Figure S1a) we investigated
the cellular uptake of raltegravir at short time points (up to 5 min).
We found that the linearity of the uptake (associated exclusively
with influx transporters) was very short, particularly in CEM-P-gp
cells (Figure S1b) and remarkably, up to 1 min, the uptake of
both cell lines was very similar (see insert). At longer time points,
the notable differences in raltegravir intracellular levels were
mostly due to higher raltegravir efflux via P-gp.
In raltegravir accumulation experiments at 30 min (Figure 1b),
the CAR of raltegravir in CEM-WT was 3.04+0.62 (normalized
to 100% for relative comparisons). The treatment with the
MRP1-specific (MK571) and P-gp-specific (XR9051) inhibitors, either
alone or in combination, did not affect the drug accumulation ratio
in these cells. For CEM-MRP1 cells we found a reduction in intracel-
lular raltegravir accumulation of .30% in untreated cells (control)
with respect to control CEM-WT cells (CAR raltegravirMRP1/CAR
raltegravirWT¼0.64, P,0.0001), but neither MK571 nor XR9051
affected raltegravir accumulation. In CEM-P-gp cells, in contrast,
the effect of P-gp function in raltegravir efflux was clear; while
untreated cells (control) showed a significant 52% reduction with
respect to CEM-WT (CAR raltegravirP-gp/CAR raltegravirWT¼0.48,
P,0.0001), the presence of XR9051 significantly increased accu-
mulation of raltegravir, either alone (P¼0.0017) or in combination
with MK571 (P¼0.0077). This demonstrates the involvement of
P-gp in raltegravir efflux in T lymphocytes.
The HIV-1 PIs, saquinavir and ritonavir, are known substrates
and inhibitors of both MRP1 and P-gp in vitro and in vivo.35,36
Thus, as a positive control of our experimental approach and of
optimal MRP1 and P-gp activity in CEM cells, we performed intracel-
lular accumulation experiments with the PI ritonavir (Figure 1c). As
found for raltegravir, ritonavir accumulation was higher in control
CEM-WT cells than in CEM-MRP1 (P¼0.015) or CEM-P-gp cells
(P,0.0001). Of note, reversan (an inhibitor of both MRP1 and
P-gp) reversed in part this phenomenon in MRP1 (P¼0.037) and
P-gp overexpressing cells (P¼0.0021).
In conclusion, raltegravir intracellular accumulation depends
on P-gp as demonstrated by CD4+ T lymphoblastoid CEM P-gp
overexpressing cells. MRP1 does not significantly contribute to
raltegravir cellular efflux.
Raltegravir in vitro drug–drug interaction(s) with PIs
After demonstrating that ritonavir is a good substrate of both
MRP1 and P-gp in our system, we tested whether we could inhibit
raltegravir efflux through these ABC transporters in CEM cells by
competing in the presence of ritonavir or saquinavir (Figure 2a).
As for the specific inhibitors, both PIs significantly competed
with raltegravir efflux in CEM-P-gp cells (saquinavir, P,0.0001;
ritonavir, P¼0.0001), whereas they did not affect raltegravir intra-
cellular accumulation in CEM-WT or CEM-MRP1. Interestingly, in
the presence of 100 mM cold raltegravir we found no changes in
[3H]raltegravir accumulation neither in CEM-WT, CEM-MRP1 nor in
CEM-P-gp. This result demonstrates that, even though being a sub-
strate, raltegravir itself is not an inhibitor of MRP1 or P-gp function
either because, by competing with the cold drug, we did not reach
saturating concentrations, or it is not an allosteric inhibitor.
Using PIs as control substrates (Figure 2b), we performed
[3H]ritonavir (1 mM) CAR experiments in the presence of 100 mM
cold saquinavir, ritonavir and raltegravir. In CEM-MRP1, only cold
ritonavir was capable of significantly increasing the CAR of
[3H]ritonavir by 25% (P,0.005). In CEM-P-gp cells, both saquina-
vir and ritonavir significantly increased the CAR of ritonavir (by
30% for saquinavir and 60% for ritonavir, P,0.005 and
P,0.001). Cold raltegravir did not inhibit MRP1 or P-gp activity
in CEM-MRP1 or CEM-P-gp, as previously suggested elsewhere30
either using [3H]raltegravir or [3H]ritonavir as a substrate.
Using a fluorescence-based assay in CEM-WT and CEM-P-gp
cells, we found a clearly reduced calcein accumulation in P-gp
overexpressing cells compared with CEM-WT (Figure 2c). Of
note, we could reverse this effect by using verapamil (a broad-
spectrum ABC transporter inhibitor) and ritonavir, but not ralte-
gravir. Assessing the fluorescence by flow cytometry, we tested
the inhibition potency of different efflux transporter inhibitors,
as well as a battery of HIV-1 PIs. The P-gp-specific XR9051
(1 mM), the broad-spectrum verapamil (20 mM) and Ko143
(50 mM) were the best inhibitors of P-gp function (see MFI
[calcein]P-gp/[calcein]WT in Table 1 and histograms in Figure S2).
The MRP1-specific inhibitor MK571 did not alter the accumulation
in CEM-P-gp, whereas it did affect, although slightly, the accumu-
lation of calcein in CEM-MRP1 (Table 1). Among the PIs tested,
amprenavir, atazanavir, lopinavir, ritonavir and saquinavir
(but not indinavir, which only inhibited MRP1, although to a lesser
extent) affected calcein accumulation in both MRP1 and P-gp
overexpressing cells significantly increasing the intracellular fluor-
escent signal (Table 1 and Figure S2). Regarding NNRTIs, only
efavirenz inhibited MRP1 and P-gp function showing a 4.9-fold
higher effect in P-gp cells (Table 1). Remarkably, raltegravir used
up to 1 mM did not alter calcein accumulation in any cell type
confirming a poor/null inhibitory effect on P-gp efflux activity.
Overall, these radiolabelled, and fluorescent-based experi-
ments, demonstrate HIV-1 PIs/raltegravir drug–drug interactions
at the P-gp level and confirms raltegravir as a null P-gp inhibitor
in vitro.
Raltegravir intracellular levels are significantly reduced
in primary CD31CD41P-gphigh cells
After assessing the substrate specificity of P-gp for raltegravir in
the lymphoblastoid CD4+ T cell model CEM cells, we aimed to
test raltegravir intracellular accumulation in primary CD4+ T
cells. To do so, we used the P-gp-specific fluorescent dye
Rho123 to distinguish between CD4+ T cell subsets with differen-
tial activity of P-gp in PBMCs from healthy donors. As shown in
Figure 3(a), gating in CD3+CD4+ T cells, we could distinguish
between two subpopulations based on Rho123 fluorescence:
the Rho123 very low (P-gp activity high; P-gphigh) and Rho123
high (P-gp activity low; P-gplow). Thus, we sorted these two popu-
lations to perform drug cellular accumulation experiments with
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[3H]raltegravir (30 min) (Figure 3b). In accordance with our results
in CEM cells, CD3+CD4+P-gphigh cells effluxed raltegravir more
efficiently than P-gplow cells, accumulating from 30% to 50%
(38.4%+9.6%) less intracellular raltegravir (P¼0.0097). Most
importantly, when incubating the cells with the P-gp-specific
inhibitor XR9051, we could significantly reverse this effect
(P¼0.017). Furthermore, when using total unsorted PBMCs, we
found a difference in intracellular levels of [3H]raltegravir versus
CD4+P-gplow cells (P¼0.034), not only due to the presence of a
significant amount of CD8+ T cells and NK cells, known to have
really high P-gp activity,26 but also to the small fraction of CD4+
T cells P-gphigh. Of note, the decrease in raltegravir accumulation
could also be reversed by XR9051 inhibitor (P¼0.017). This is the
first demonstration of raltegravir efflux via P-gp in primary CD4+
T cells.
HIV-1 infection increases P-gp expression in vitro and
P-gphigh cells sustain higher HIV-1 infection rates
Next, we studied whether HIV-1 infection was capable of altering
P-gp expression and/or activity. Thus, we assessed the effect of
HIV-1 infection on P-gp expression in PBMCs cultured in either
IL-2 alone or in IL-2 plus PHA (Figure 4a). P-gp mRNA expression
significantly increased from 1.7- to 2.4-fold when the cells were
infected with HIV-1NL4-3 (CXCR4-tropic strain) and cultured in
IL-2 only, with the strongest effect found at moi 0.1. When cells
were infected after 3 days activation in PHA, the increase in P-gp
mRNA expression varied from 1.5- to 3.6-fold.
We also assessed P-gp activity by calcein efflux after PHA acti-
vation in three different primary samples from blood donors
(Figure 4b). In CD4+ T lymphocytes, we found an overall dramatic
decrease in calcein accumulation (red histogram) in accordance
to a strong overall activation of P-gp activity. When using
the P-gp-specific inhibitor XR9051 in non-stimulated CD4+, the
activity of P-gphigh cells was remarkably inhibited seen as a drastic
reduction in calcein efflux (peak between 101 and 102 in Figure 4b;
see black arrows).
Finally, we also tested HIV-1 infection levels in primary
CD3+CD4+P-gplow and P-gphigh subsets. Surprisingly, after
6 days post-infection, P-gphigh cells showed a significantly higher
level of intracellular HIV-1 p24Gag antigen. The effect was present
in the three donors tested even though the infection levels were
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Figure 2. Inhibition of raltegravir and model substrate ritonavir efflux by HIV-1 PIs saquinavir and ritonavir. (a) [3H]Raltegravir (1 mM; 0.5 mCi/mL) was
incubated for 30 min in CEM cells in the absence (control) or presence of 100 mM saquinavir, ritonavir or raltegravir in the extracellular site and CAR was
determined. (b) [3H]Ritonavir (1 mM; 1 mCi/mL) was incubated for 30 min with CEM cells in the absence (control) or presence of 100 mM saquinavir,
ritonavir or raltegravir. Results are expressed as the percentage of CAR normalized to CEM-WT cells (control cells) and represent the mean+SEM of
three independent experiments performed in duplicate. Statistical significance between each control CEM-WT, CEM-MRP1 and CEM-P-gp and
between control and PI or raltegravir treatment was assessed by paired t-test (**P,0.01; ***P,0.001). (c) Cis-inhibition of the fluorescent substrate
calcein in CEM-WT and CEM-P-gp cells. Calcein-AM (0.25 mM) was incubated for 20 min at 378C in CEM-WT or CEM-P-gp in the absence or presence of
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live culture cells by fluorescence microscopy. Ctrl, control; RAL, raltegravir; RTV, ritonavir; SQV, saquinavir. This figure appears in colour in the online version
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very different (particularly in donor 3). The p24Gag levels increased
dramatically at days 9, 11 and 13 post-infection (particularly in
donors 2 and 3) in P-gphigh cells, whereas P-gplow cells showed a
very slight or null increase. These data suggest that P-gphigh cells
are a more activated subtype of CD4+ T cells that can sustain a
higher HIV-1 replication rate. Overall, these experiments suggest
P-gp activation (by both protein activity and mRNA expression)
after HIV-1 infection and, surprisingly, a differential infection
effect on CD4+P-gphigh and P-gplow cells.
Correlation between P-gp activity and HIV-1 viral
load in CD41 T cell subsets
We then tested whether different CD4+ T cell subsets show
correlation between P-gp activity and HIV-1 viral load, by analys-
ing the percentage of total P-gp active cells of specific T cell
subsets versus viral load (in log10 copies of HIV-1 RNA per mL)
of each HIV-1-infected subject (see the Materials and methods
section). As shown in Figure 5(a–c), CD4+ T cells (r¼0.505,
P¼0.033), CD4+CCR5+ (r¼0.538, P¼0.021) and double positive
CCR5+CXCR4+ cells (r¼0.571, P¼0.013) showed a positive
correlation between the increase in HIV-1 viral load and percent-
age of P-gp active cells. The most significant correlation between
HIV-1 viral load and P-gp active cells was found within the
memory CD4+ T cell subset (defined as CD4+CD45RA2)
(r¼0.792, P,0.0001) (Figure 5d). Similar correlations were
also found for central memory CD4+ T cells (TCM, defined as
CD4+CD45RA2CD27+CCR7+) (r¼0.572, P¼0.013) (Figure 5e)
and transitional memory CD4+ T cells (TTM, defined as
CD4+CD45RA2CD27+CCR72) (r¼0.536, P¼0.022) (Figure 5f).
As hypothesized, both CD4+ T cells and memory CD4+ T cells,
including some of their subsets showed a significant correlation
between HIV-1 viral load in plasma and P-gp activity. This import-
ant finding suggests HIV-1 cellular activation as a key factor in
modulating P-gp efflux activity.
Discussion
Experiments performed in our CD4+ T cell models confirmed an
efflux transport of raltegravir by P-gp and a significant inhibition
with the P-gp-specific blocker XR9051 as previously reported
using different P-gp inhibitors.29,30 In accordance with these pre-
vious reports, raltegravir seemed a relatively ‘poor’ substrate of
P-gp in comparison with ritonavir, an HIV PI used as a control sub-
strate (Figure 1b and c). However, the transporter could still be
relevant in vivo and influence the pharmacokinetic/pharmacody-
namic relationship or the drug clinical response. Moreover, Moss
et al.30 described reduced HIV PI uptake in CEM-MRP1 and
CEM-P-gp versus CEM-WT cells, but their measurements started
at 1 min, when, according to our measurements (Figure S1), the
linear uptake phase is already ended. Thus, the contribution of
uptake transport in the experiments performed at longer time
points than 5 min is residual.
In parallel we ruled out MRP1 as an efflux transporter for ralte-
gravir and confirmed previously shown null inhibition of P-gp func-
tion by raltegravir.29,30 This, along with evidence showing that
ritonavir and other HIV-1 PIs efficiently inhibited its own and
raltegravir efflux, suggests that P-gp has a translocation binding
site for raltegravir and a spatially separated site, where other
drugs could act as allosteric inhibitors.37 Ritonavir could be com-
peting for the transport in the translocation site or allosterically
inhibiting its own efflux, binding to a different (extra- or intracel-
lular) site of P-gp. Of note, as for raltegravir, many P-gp substrates
are not suitable inhibitors of the ATP-efflux transporter38 and the
occurrence of binding sites with different functional properties has
been also reported for the SLC superfamily of transporters (e.g.
OCT1).39,40
This study also showed that most HIV-1 PIs (except for indinavir)
inhibited both MRP1 and P-gp function. The latter phenomenon
would be relevant for raltegravir drug disposition and pharmacokin-
etics as raltegravir is usually co-administered with PIs, particularly
darunavir or atazanavir, both ‘boosted’ with ritonavir.1 However,
atazanavir increases raltegravir systemic exposure by inhibiting its
main metabolizing enzyme UDP-glucuronosyltransferase 1 family
polypeptide 1A (UGT1A1).41 On the other hand, darunavir has
been recently shown to inhibit P-gp activity in vitro;42 thus, if affect-
ing the pump in vivo, its co-administration with raltegravir would
favour its persistence in certain cell subsets with high P-gp activity.
In radiolabelled experiments with CEM-P-gp cells in the presence of
saquinavir and ritonavir, raltegravir showed 20%–40% higher intra-
cellular accumulation. Assuming that plasma concentrations of PIs
in patients are sufficient to inhibit P-gp activity, favourable drug–
drug interactions could be occurring at this level. Some previous
Table 1. Calcein fluorescence ratio values normalized to CEM-WT
(CEM-CCRF) untreated cells as found by flow cytometry analysis
Treatment
Fluorescence ratio (MFI treated/MFI mock cells)
CEM-WT CEM-MRP1 CEM-P-gp
Untreated (mock) 1.00 0.181 0.018
Efflux inhibitors
Ko143 0.77 2.80 14.38
verapamil 1.18 5.34 40.12
MK571 1.16 2.53 1.20
XR9051 0.94 0.90 20.99
PIs
amprenavir 0.87 3.49 47.53
atazanavir 0.63 2.54 47.97
ritovanir 0.87 5.00 65.41
saquinavir 0.77 3.94 37.94
indinavir 1.28 2.11 2.21
lopinavir 0.60 4.20 39.03
NNRTIs
efavirenz 0.94 4.38 21.49
nevirapine 0.92 1.23 2.02
INIs
raltegravir 1 mM 0.77 1.13 1.04
raltegravir 10 mM 1.16 1.21 1.18
raltegravir 100 mM 1.18 1.31 1.35
raltegravir 1 mM 0.54a 0.51a 2.03
Values .2.50 are highlighted in bold.
aDecrease in fluorescence ratio due to low raltegravir solubility at 1 mM.
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pharmacokinetic reports only indicate remarkable interactions
between atazanavir41 and raltegravir, but no other PIs.43,44
However, the lack of fine experimental techniques to detect effi-
ciently the intracellular drug levels in different blood cell subsets
may mask relevant interactions45–47 responsible for the high vari-
ability in raltegravir levels in patients.19,20 Most importantly, subsets
of primary CD3+CD4+ cells with remarkable different P-gp activity
(namely P-gphigh and P-gplow; see Figure 3) showed variable intra-
cellular raltegravir concentrations. The extracellular treatment of
the CD4+P-gphigh with the P-gp-specific blocker XR9051, signifi-
cantly increased the intracellular accumulation of raltegravir, indi-
cating that P-gp is important for its intracellular disposition in
primary CD4+ T cells. In addition, we assessed the possible contri-
bution of BCRP1 (another relevant ABC transporter), which has been
reported to be expressed with high inter-individual variability on cir-
culating CD4+ T cells.48 Compared with P-gp, we found negligible
ABCG2 mRNA and BCRP1 protein expression in CEM-MRP1,
CEM-P-gp, freshly isolated PBMCs and primary CD4+ T cells
(Figure S3), as well as a null inhibition of calcein accumulation in
the presence of low doses (,1 mM) of Ko143 in the latter cells
(data not shown). Whether the reduction in raltegravir levels in
these cells could be affecting drug activity and HIV-1 suppression
in vivo is something that needs further investigation. However, we
hypothesize that long-lasting CD4+ T cell subsets (such as CD4+
TCM cells) with high P-gp activity would be partially refractory to ral-
tegravir (or other HIV-1 drugs that are substrates for P-gp) and
could represent HIV-1 cellular reservoirs in vivo. Recently, a small
proportion of CD4+ memory T cells with stem-cell like properties
(termed CD4+ TSCM) have been described as HIV-1 long-term reser-
voirs; this subset can harbour high levels of HIV-1 DNA and signifi-
cantly contribute to HIV-1 persistence.14 In accordance, it is well
known that haematopoietic stem cells have high levels of P-gp49
and other efflux pumps (i.e. BCRP). Thus, in addition to containing
fewer HIV-1 restriction factors,14 CD4+ stem cell-like memory T
cells (TSCM) may also be more refractory to the HAART regimen
due to higher levels or activity of P-gp or other efflux transporters.
Interestingly, it has also been suggested that transcriptionally qui-
escent thymocytes (CD3highCD27+) and NK cells, showing high
P-gp activity, may be a pharmacological sanctuary site for
HIV-1.34,50
We then addressed the question of whether the virus and cel-
lular activation influences P-gp activity by infecting CD4+ T cells in
vitro, in the presence of IL-2 or IL-2/PHA. HIV-1 infection signifi-
cantly increased mRNA expression of P-gp, and the activation of
CD4+ T cells by PHA showed increased P-gp activity, an effect
that could be reversed by the P-gp-specific inhibitor XR9051, in
unstimulated primary CD4+ T cells. In studies done in human
and rat astrocytes, IL-6 secretion after HIV-1 glycoprotein
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Figure 3. Raltegravir intracellular accumulation analysis of CD3+CD4+P-gphigh and P-gplow populations. (a) After Rho123 incubation (1 mM, 20 min,
378C), PBMCs were put in culture (complete medium) during 2 h to let the dye be effluxed and then stained with anti-CD3-APC and anti-CD4-PerCP
antibodies. CD3+CD4+ T cells were sorted based on their Rho123 staining: P-gphigh (Rho123 very low) and P-gplow (Rho123 high). Cells were directly
used in subsequent [3H]raltegravir accumulation assays. (b) CD3+CD4+P-gphigh and CD3+CD4+P-gplow cells were incubated in transport medium
with 1 mM (1 mCi/mL) [3H]raltegravir in the absence (mock) or presence of the P-gp-specific inhibitor XR9051 (1 mM). Unsorted (total) PBMCs were
used as control of viability and transport, considering that they contain CD8+ T cells, NK and monocytes. The results represent the mean+SEM of
five independent experiments (each with a different blood donor) performed in duplicate. Statistical significance was assessed by paired t-test
(*P,0.05; **P,0.01; n¼5). This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
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gp120 treatment decreases the P-gp expression and activ-
ity,51,52 whereas only TNF-a increases P-gp and MRP1 expression,
but not IL-1b or IL-6, for the latter transporter.52,53 More import-
antly, we found that sorted CD4+P-gphigh cells achieved higher
levels of HIV-1 replication (by p24Gag antigen) than P-gplow cells,
most probably due to a higher activation rate of these cells. The
same effect was confirmed in our CD4+ T lymphoblastoid cell
models (CEM-P-gp versus CEM-WT). In accordance, previous
findings demonstrated a more prominent depletion of HIV-1
infection on CD4+CCR5+with high expression of P-gp26 contrary
to the hypothesis that high P-gp expression can confer a protect-
ive effect against HIV-1 infection by steric hindrance or other
physicochemical properties.36,52 In their work, Valentin et al.26
described that 15% – 33% of in vitro HIV-1-infected PBMCs
have high P-gp activity, but they did not compare HIV replication
rates between CD4+P-gphigh and P-gplow subsets. Furthermore,
they found a decrease in CD4+CCR5+P-gphigh cells in
HIV-1-infected individuals versus HIV-1 seronegative donors.
In our patient cohort, we observed a similar trend for
CD4+CXCR4+, where the percentage of P-gphigh was decreased
in HIV-1-infected subjects versus HIV-1 seronegative individuals
and in high viraemic (.100000 copies/mL) versus low viraemic
(,30000 copies/mL) HIV-1-infected patients (data not shown).
This suggests the need for a high viral presence in the blood
to deplete selectively the CD4+P-gphigh cell populations.
Importantly, high viraemic HIV-1-infected subjects show
lower raltegravir rate success than low viraemic subjects in
both naive16 and treatment-experienced patients54 with
drug-resistant HIV infection. Furthermore, the nucleoside-
sparing regimen of darunavir/ritonavir plus raltegravir showed
a higher rate of virological failure and integrase resistance in
high viraemic patients.55 Thus, we should consider the long-
term survival of the residual percentage of CD4+P-gphigh cells
(expressing HIV-1 co-receptors) as a putative cause for HIV-1
latency, drug resistance and virological failure as they would
represent a cellular reservoir.
Most importantly, we found a significant correlation between
HIV-1 viral load and P-gp activity [considering total P-gp active
cells as reported by Haraguchi et al.,34 not only the P-gp very
active (P-gphigh) population] in different subsets of CD4+ T cells:
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Figure 4. Effect of HIV-1 infection and cellular activation on P-gp expression and activity. (a) P-gp mRNA levels were assessed by quantitative real-time
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the higher the viral load, the higher the P-gp activity in CD4+
T cells. The greatest correlation was found in the whole population
of memory T cells (CD3+CD4+CD45RA2) (Figure 5d; r¼0.792,
P,0.0001). Of note, central memory (TCM)—very long-lived
cells—and transitional memory T cells (TTM) showed a correlation
between increase in viral load and P-gp activity. Other groups have
studied ABC transporters mRNA expression or P-gp and MRP activ-
ity in infected patients, but the results are controversial, mostly
due to different methods employed and the heterogeneity in
the populations and drug treatments compared.35,46,47,56,57 Of
note, Turriziani et al.57 found a higher mRNA expression of the
genes encoding for P-gp, MRP1, MRP4 and MRP5 in HIV-positive
patients in comparison with healthy donors. In contrast,
Meaden et al.47 found a decrease in membrane P-gp expression
by flow cytometry in PBMCs of HIV-1-positive individuals (17 of
a total of 21, on HAART). In our study, the increase in P-gp activity
in the presence of high viral load in HIV-1-infected subjects, sug-
gests an important phenomenon in vivo: a higher virus presence in
blood would mean a higher T cell activation and a higher efflux
transport mechanism of P-gp. Overall, HIV-1-associated cell acti-
vation increases P-gp activity, but, at the same time, P-gphigh cells
are also more susceptible to HIV-1 infection, to HIV-related apop-
tosis and more refractory to PIs and raltegravir. Thus, the percent-
age of CD4+P-gphigh subsets that would be infected and would
survive with the integrated virus, could represent a population
with persistent HIV-1 and a threat for HIV-1 eradication as previ-
ously suggested for mature thymocytes34 and demonstrated for
NK cells50 and stem-cell like CD4+ (TSCM) cells.14 Better character-
ization of the different P-gphigh Tcell subsets and deciphering if the
novel stem cell-like CD4+ (TSCM) cells have high levels of P-gp (or
other ABC transporters) would help to find ways to target it more
efficiently, increasing raltegravir and PI clinical outcome and min-
imizing HIV-1 persistence.
Overall, we have demonstrated an important role of P-gp for
raltegravir efflux in primary CD4+ cells and the in vivo effect of
HIV-1 on the activity of the transporter. Higher levels of virus in
the blood increase P-gp efflux and might decrease drug regimen
success. However, the CD4+P-gphigh cells are also more readily
depleted by HIV-1. Thus, HIV-1 plasma levels and the clearance
of CD4+P-gphigh subsets might influence treatment efficacy,
particularly when systemic exposure to raltegravir is not
warranted.
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Figure 5. P-gp activity correlation with plasma viral load in different CD4+ subsets in HIV-1-infected subjects. HIV-1-infected blood samples were
processed by Ficoll-Paque to obtain the PBMC fraction and loaded with Rho123. After 2 h of efflux time, cells were stained with two panels of
antibodies (plus CD3-APC and CD4-PerCP, present in both panels): (i) HIV-1 co-receptors, CXCR4 and CCR5; and (ii) naive/memory populations
(CD45RA, CD27, CCR7). CD3+CD4+, CD4+CCR5+ and double positive (CD4+CCR5+CXCR4+) populations and their correlations with plasma viral load
(HIV-1 RNA log copies/mL) are shown in (a), (b) and (c), respectively. (d), (e) and (f) show CD4+CD45RA2 (memory T cells), CD45RA2CD27+CCR7+ (T
central memory, TCM) and CD45RA2CD27+CCR72 (T transitional memory, TTM) correlations. Statistical analyses were performed by Spearman
correlations (r) of percentage of P-gp active cells versus viral load. Statistically significant P values ,0.05 are shown together with r values.
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